Mar 4, 2024
Today the first MGH patients received lecanemab infusions for early-stage Alzheimer’s disease. We have been working diligently with our colleagues at the Brigham to develop uniform procedures for identifying the appropriate candidates for this new class of treatment, and setting up protocols to be able to safely and effectively deliver this new treatment.
“Today felt like the dawning of a new era in my clinical practice. When I saw patients receiving this medication in the medical infusion center, I felt deeply satisfied that the research to which that so many scientists, medical professionals, and patients and families have contributed has brought us to a point where patients are now receiving this therapy in our standard medical practice. We will keep striving to help appropriate patients access this treatment and to advance our repertoire of other kinds of treatments beyond this important step forward.” – Brad Dickerson, MD